Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSY-05001
- Development stage
- Unknown
- Lead developer
- Psy Therapeutics
- Modality
- Small Molecules
01
Overview
PSY-05001 is a small molecule drug candidate developed by Psy Therapeutics for the treatment of chronic pain and sleep disturbance, particularly in patients with post-traumatic stress disorder (PTSD). The compound is being advanced as a brain-penetrant, well-tolerated therapy designed to address unmet needs in neuropsychiatric and neurological disorders. As of June 2025, PSY-05001 has reached the IND (Investigational New Drug) application stage and is not yet in clinical trials. Its primary therapeutic area is analgesia within nervous system diseases. Specific molecular targets or mechanisms of action have not been publicly disclosed[1][2][3].
Beyond the preview
Go deeper on PSY-05001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSY-05001.